G
Georgia D. Tomaras
Researcher at Duke University
Publications - 389
Citations - 25248
Georgia D. Tomaras is an academic researcher from Duke University. The author has contributed to research in topics: Antibody & Vaccination. The author has an hindex of 69, co-authored 351 publications receiving 22039 citations. Previous affiliations of Georgia D. Tomaras include HIV Vaccine Trials Network & Durham University.
Papers
More filters
Journal ArticleDOI
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele,Elena E. Giorgi,Elena E. Giorgi,Jesus F. Salazar-Gonzalez,Julie M. Decker,Kimmy T. Pham,Maria G. Salazar,Chuanxi Sun,Truman Grayson,Shuyi Wang,Hui Li,Xiping Wei,Chunlai Jiang,Jennifer L. Kirchherr,Feng Gao,Jeffery A. Anderson,Li Hua Ping,Ronald Swanstrom,Georgia D. Tomaras,William A. Blattner,Paul A. Goepfert,J. Michael Kilby,Michael S. Saag,Eric Delwart,Michael P. Busch,Myron S. Cohen,David C. Montefiori,Barton F. Haynes,Brian Gaschen,Gayathri Athreya,Ha Y. Lee,Natasha T. Wood,Cathal Seoighe,Alan S. Perelson,Tanmoy Bhattacharya,Tanmoy Bhattacharya,Bette T. Korber,Bette T. Korber,Beatrice H. Hahn,George M. Shaw +39 more
TL;DR: A mathematical model of random viral evolution and phylogenetic tree construction is developed and used to analyze 3,449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection, suggesting a finite window of potential vulnerability of HIV- 1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.
Journal ArticleDOI
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes,Peter B. Gilbert,M. Juliana McElrath,Susan Zolla-Pazner,Georgia D. Tomaras,S. Munir Alam,David T. Evans,David C. Montefiori,Chitraporn Karnasuta,Ruengpueng Sutthent,Hua-Xin Liao,Anthony L. DeVico,George K. Lewis,Constance Williams,Abraham Pinter,Youyi Fong,Holly Janes,Allan C. deCamp,Yunda Huang,Mangala Rao,Erik Billings,Nicos Karasavvas,Merlin L. Robb,Viseth Ngauy,Mark de Souza,Robert Paris,Guido Ferrari,Robert T. Bailer,Kelly A. Soderberg,Charla Andrews,Phillip W. Berman,Nicole Frahm,Stephen C. De Rosa,Michael D. Alpert,Nicole L. Yates,Xiaoying Shen,Richard A. Koup,Punnee Pitisuttithum,Jaranit Kaewkungwal,Sorachai Nitayaphan,Supachai Rerks-Ngarm,Nelson L. Michael,Jerome H. Kim +42 more
TL;DR: V vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.
Journal ArticleDOI
The immune response during acute HIV-1 infection: clues for vaccine development.
TL;DR: The finding that the first effective immune responses drive the selection of virus escape mutations provides insight into the earliest immune responses against the transmitted virus and their contributions to the control of acute viraemia.
Journal ArticleDOI
Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia
Georgia D. Tomaras,Nicole L. Yates,Pinghuang Liu,Li Qin,Genevieve G. Fouda,Leslie L. Chavez,Allan C. deCamp,Robert Parks,Vicki C Ashley,Judith T. Lucas,Myron S. Cohen,Joseph J. Eron,Charles B. Hicks,Hua-Xin Liao,Steven G. Self,Gary Landucci,Donald N. Forthal,Kent J. Weinhold,Brandon F. Keele,Beatrice H. Hahn,Michael L. Greenberg,Lynn Morris,Salim S. Abdool Karim,William A. Blattner,David C. Montefiori,George M. Shaw,Alan S. Perelson,Barton F. Haynes +27 more
TL;DR: It is demonstrated that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection.
Journal ArticleDOI
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer,Magdalena E. Sobieszczyk,Holly Janes,Shelly Karuna,Mark J. Mulligan,Doug Grove,Beryl A. Koblin,Susan Buchbinder,Michael C. Keefer,Georgia D. Tomaras,Nicole Frahm,John Hural,Chuka Anude,Barney S. Graham,Mary E. Enama,Elizabeth Adams,Edwin DeJesus,Richard M. Novak,Ian Frank,Carter Bentley,Shelly Ramirez,Rong Fu,Richard A. Koup,John R. Mascola,Gary J. Nabel,David C. Montefiori,James G. Kublin,M. Juliana McElrath,Lawrence Corey,Peter B. Gilbert +29 more
TL;DR: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied and had an acceptable side-effect profile.